JP2023533938A5 - - Google Patents
Info
- Publication number
- JP2023533938A5 JP2023533938A5 JP2023500011A JP2023500011A JP2023533938A5 JP 2023533938 A5 JP2023533938 A5 JP 2023533938A5 JP 2023500011 A JP2023500011 A JP 2023500011A JP 2023500011 A JP2023500011 A JP 2023500011A JP 2023533938 A5 JP2023533938 A5 JP 2023533938A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- cancer
- compound
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019094634 | 2019-07-04 | ||
| CNPCT/CN2020/100134 | 2020-07-03 | ||
| PCT/CN2020/100134 WO2021000935A1 (en) | 2019-07-04 | 2020-07-03 | Hpk1 inhibitors and uses thereof |
| PCT/CN2021/104206 WO2022002237A1 (en) | 2019-07-04 | 2021-07-02 | Hpk1 inhibitors and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023533938A JP2023533938A (ja) | 2023-08-07 |
| JP2023533938A5 true JP2023533938A5 (https=) | 2024-07-10 |
| JP7759374B2 JP7759374B2 (ja) | 2025-10-23 |
Family
ID=74100919
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022500151A Active JP7633989B2 (ja) | 2019-07-04 | 2020-07-03 | Ｈｐｋ１阻害剤およびその使用 |
| JP2023500011A Active JP7759374B2 (ja) | 2019-07-04 | 2021-07-02 | Ｈｐｋ１阻害剤およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022500151A Active JP7633989B2 (ja) | 2019-07-04 | 2020-07-03 | Ｈｐｋ１阻害剤およびその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12612424B2 (https=) |
| EP (2) | EP3994133A4 (https=) |
| JP (2) | JP7633989B2 (https=) |
| KR (2) | KR20220044495A (https=) |
| CN (2) | CN114555585B (https=) |
| AU (2) | AU2020298649B2 (https=) |
| BR (1) | BR112022000064A2 (https=) |
| CA (1) | CA3145973A1 (https=) |
| DK (1) | DK4175951T3 (https=) |
| ES (1) | ES2981368T3 (https=) |
| FI (1) | FI4175951T3 (https=) |
| IL (1) | IL289612B2 (https=) |
| MA (1) | MA56462A (https=) |
| MX (2) | MX2022000271A (https=) |
| TW (1) | TWI878319B (https=) |
| WO (2) | WO2021000935A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11203591B2 (en) | 2018-10-31 | 2021-12-21 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| MA56462A (fr) | 2019-07-04 | 2022-05-11 | Qilu Regor Therapeutics Inc | Inhibiteurs de hpk1 et leurs utilisations |
| TW202140473A (zh) | 2020-01-15 | 2021-11-01 | 美商纜圖藥品公司 | Map4k1抑制劑 |
| WO2022063140A1 (en) * | 2020-09-23 | 2022-03-31 | Shenzhen Ionova Life Science Co., Ltd. | Pyrimidine and pyridine derivatives as hpk1 modulator and methods using same |
| CN117024445B (zh) * | 2020-10-28 | 2025-08-08 | 杭州阿诺生物医药科技有限公司 | 用于制备hpk1激酶抑制剂的化合物及其合成方法 |
| EP4291235A4 (en) * | 2021-02-12 | 2025-01-08 | Nimbus Saturn, Inc. | HPK1 ANTAGONISTS AND USES THEREOF |
| US11926625B2 (en) * | 2021-03-05 | 2024-03-12 | Nimbus Saturn, Inc. | HPK1 antagonists and uses thereof |
| EP4305041A1 (en) * | 2021-03-08 | 2024-01-17 | Blueprint Medicines Corporation | Map4k1 inhibitors |
| CN117295748A (zh) * | 2021-03-08 | 2023-12-26 | 缆图药品公司 | Map4k1抑制剂 |
| CN116854687B (zh) * | 2021-03-23 | 2025-07-25 | 杭州阿诺生物医药科技有限公司 | Hpk1激酶抑制剂化合物 |
| WO2022213062A1 (en) | 2021-03-29 | 2022-10-06 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
| CN117377673A (zh) * | 2021-03-29 | 2024-01-09 | 林伯士萨顿公司 | Hpk1拮抗剂和其用途 |
| TW202304906A (zh) * | 2021-04-08 | 2023-02-01 | 大陸商杭州阿諾生物醫藥科技有限公司 | 高活性hpk1激酶抑制劑 |
| WO2023288254A1 (en) * | 2021-07-14 | 2023-01-19 | Blueprint Medicines Corporation | Heterocyclic compounds as map4k1 inhibitors |
| TW202321239A (zh) | 2021-07-20 | 2023-06-01 | 瑞典商阿斯特捷利康公司 | 作為ｈｐｋ１抑制劑用於治療癌症之經取代的吡𠯤—２—甲醯胺 |
| WO2023083299A1 (zh) * | 2021-11-12 | 2023-05-19 | 微境生物医药科技(上海)有限公司 | 作为hpk1抑制剂的稠环化合物 |
| CN118434729A (zh) * | 2022-01-11 | 2024-08-02 | 微境生物医药科技(上海)有限公司 | 作为hpk1抑制剂的稠环化合物 |
| WO2023245329A1 (en) * | 2022-06-20 | 2023-12-28 | Biofront Ltd | Multi-kinase inhibitors, compositions thereof, and methods of using the same |
| CN116813692A (zh) * | 2023-06-29 | 2023-09-29 | 凌科药业(杭州)有限公司 | 含磷化合物、其药物组合物及其用途 |
| WO2025096647A1 (en) * | 2023-10-30 | 2025-05-08 | Nimbus Saturn, Inc. | Methods of treating tumors |
| WO2025137168A2 (en) | 2023-12-19 | 2025-06-26 | Regor Pharmaceuticals, Inc. | Salt and solid forms of a hpk1 inhibitor |
| WO2025255343A1 (en) * | 2024-06-06 | 2025-12-11 | Dana-Farber Cancer Institute, Inc. | Pyrrolopyrimidine inhibitors of wild-type and mutant lrrk2 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003028724A1 (en) | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
| UA95244C2 (ru) | 2005-06-22 | 2011-07-25 | Плексикон, Инк. | Соединения и способ модулирования активности киназ, и показания для их применения |
| US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US20070087988A1 (en) | 2005-09-30 | 2007-04-19 | New York University | Hematopoietic progenitor kinase 1 for modulation of an immune response |
| WO2007135398A1 (en) | 2006-05-22 | 2007-11-29 | Astrazeneca Ab | Indole derivatives |
| CA2654670A1 (en) * | 2006-07-06 | 2008-01-10 | Boehringer Ingelheim International Gmbh | New compounds |
| JP2010514693A (ja) | 2006-12-22 | 2010-05-06 | ノバルティス アーゲー | Ｐｄｋ１阻害のためのキナゾリン |
| WO2008110508A1 (en) * | 2007-03-09 | 2008-09-18 | Glaxo Group Limited | Pyrrolo-pyridine derivatives for the treatment of disorders associated with inappropriate ikk1 activity |
| JPWO2009084695A1 (ja) | 2007-12-28 | 2011-05-19 | カルナバイオサイエンス株式会社 | ２−アミノキナゾリン誘導体 |
| US20100121052A1 (en) * | 2008-06-20 | 2010-05-13 | Rama Jain | Novel compounds for treating proliferative diseases |
| EP2248907A1 (en) | 2009-05-08 | 2010-11-10 | Rijksuniversiteit Groningen | Gluco-oligosaccharides comprising (alpha 1-->4) and (alpha 1-->6) glycosidic bonds, use thereof, and methods for providing them |
| US8791112B2 (en) | 2011-03-30 | 2014-07-29 | Arrien Pharmaceuticals Llc | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors |
| GB201311475D0 (en) | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Polypeptides |
| EP3096754B1 (en) | 2014-01-22 | 2018-08-29 | Merck Sharp & Dohme Corp. | Metallo-beta-lactamase inhibitors |
| CN104876914B (zh) * | 2014-02-28 | 2017-04-19 | 山东轩竹医药科技有限公司 | 嘧啶衍生物类间变性淋巴瘤激酶抑制剂 |
| US20170137426A1 (en) * | 2014-03-28 | 2017-05-18 | Changzhou Jiekai Pharmatech Co., Ltd. | Heterocyclic compounds as axl inhibitors |
| CN106188029B (zh) * | 2015-05-05 | 2018-09-18 | 山东轩竹医药科技有限公司 | 二并环类间变性淋巴瘤激酶抑制剂 |
| JP6570776B2 (ja) | 2016-06-20 | 2019-09-04 | テグ−キョンプク メディカル イノベーション ファウンデーション | 新規のイミダゾピリジン誘導体、その製造方法及びこれを有効成分として含有する癌の予防又は治療用医薬組成物 |
| WO2018002219A1 (en) * | 2016-06-30 | 2018-01-04 | Janssen Pharmaceutica Nv | Cyanoindoline derivatives as nik inhibitors |
| CN115819417A (zh) | 2016-09-09 | 2023-03-21 | 因赛特公司 | 作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途 |
| WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
| WO2018102366A1 (en) | 2016-11-30 | 2018-06-07 | Ariad Pharmaceuticals, Inc. | Anilinopyrimidines as haematopoietic progenitor kinase 1 (hpk1) inhibitors |
| WO2018152220A1 (en) | 2017-02-15 | 2018-08-23 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| EP3587422A4 (en) | 2017-02-22 | 2020-05-06 | Daegu-Gyeongbuk Medical Innovation Foundation | PYRROLOPYRIMIDINE DERIVATIVE COMPOUND, PRODUCTION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION WITH THIS COMPOUND AS AN ACTIVE SUBSTANCE FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE |
| CN110402248B (zh) | 2017-03-15 | 2023-01-06 | 豪夫迈·罗氏有限公司 | 作为hpk1抑制剂的氮杂吲哚类 |
| US20200071326A1 (en) | 2017-04-14 | 2020-03-05 | Syros Pharmaceuticals, Inc. | Tam kinase inhibitors |
| AU2018272986A1 (en) | 2017-05-26 | 2019-12-12 | Ichnos Sciences SA | Novel inhibitors of MAP4K1 |
| EP3694861A4 (en) | 2017-10-09 | 2021-05-19 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| CN109721620B (zh) | 2017-10-27 | 2022-05-13 | 药捷安康(南京)科技股份有限公司 | Hpk1抑制剂及其用途 |
| EP3707138B1 (en) | 2017-11-06 | 2022-07-13 | Bristol-Myers Squibb Company | Isofuranone compounds useful as hpk1 inhibitors |
| US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| WO2020235902A1 (ko) | 2019-05-17 | 2020-11-26 | 주식회사 보로노이 | 헤테로고리 융합 피리미딘 유도체 및 이의 용도 |
| MA56462A (fr) | 2019-07-04 | 2022-05-11 | Qilu Regor Therapeutics Inc | Inhibiteurs de hpk1 et leurs utilisations |
-
2020
- 2020-07-03 MA MA056462A patent/MA56462A/fr unknown
- 2020-07-03 IL IL289612A patent/IL289612B2/en unknown
- 2020-07-03 CN CN202080057904.1A patent/CN114555585B/zh active Active
- 2020-07-03 MX MX2022000271A patent/MX2022000271A/es unknown
- 2020-07-03 BR BR112022000064A patent/BR112022000064A2/pt not_active Application Discontinuation
- 2020-07-03 KR KR1020227003145A patent/KR20220044495A/ko active Pending
- 2020-07-03 AU AU2020298649A patent/AU2020298649B2/en active Active
- 2020-07-03 JP JP2022500151A patent/JP7633989B2/ja active Active
- 2020-07-03 WO PCT/CN2020/100134 patent/WO2021000935A1/en not_active Ceased
- 2020-07-03 EP EP20834163.6A patent/EP3994133A4/en active Pending
- 2020-07-03 CA CA3145973A patent/CA3145973A1/en active Pending
- 2020-07-03 US US17/624,514 patent/US12612424B2/en active Active
- 2020-07-03 TW TW109122604A patent/TWI878319B/zh active
-
2021
- 2021-07-02 ES ES21742686T patent/ES2981368T3/es active Active
- 2021-07-02 AU AU2021299849A patent/AU2021299849A1/en active Pending
- 2021-07-02 MX MX2023000025A patent/MX2023000025A/es unknown
- 2021-07-02 JP JP2023500011A patent/JP7759374B2/ja active Active
- 2021-07-02 FI FIEP21742686.5T patent/FI4175951T3/fi active
- 2021-07-02 DK DK21742686.5T patent/DK4175951T3/da active
- 2021-07-02 CN CN202180053862.9A patent/CN116096370B/zh active Active
- 2021-07-02 EP EP21742686.5A patent/EP4175951B1/en active Active
- 2021-07-02 KR KR1020237003551A patent/KR20230035061A/ko active Pending
- 2021-07-02 WO PCT/CN2021/104206 patent/WO2022002237A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023533938A5 (https=) | ||
| MY206521A (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| JP2014500870A5 (https=) | ||
| PH12022551014A1 (en) | Substituted tricyclic compounds | |
| JP2008535902A5 (https=) | ||
| MX2023006883A (es) | Metodos para tratar el cancer de prostata. | |
| EA201991894A1 (ru) | ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
| JP2019014758A5 (https=) | ||
| JP2023500483A5 (https=) | ||
| JP2011509949A5 (https=) | ||
| IL311873A (en) | Combination therapy for treating malignancies | |
| JP2021530453A5 (https=) | ||
| JP2015512943A5 (https=) | ||
| JP2021530487A5 (https=) | ||
| JP2019506392A5 (https=) | ||
| MX2022014192A (es) | Metodos para tratar el cancer de prostata. | |
| NZ726365A (en) | Combinations for treating cancers | |
| RU2011124894A (ru) | Триазолотиадиазоловый ингибитор протеинкиназы с-мет | |
| JP2025504379A5 (https=) | ||
| JP2021514395A5 (https=) | ||
| MX2023013715A (es) | Regímenes de dosis de ecubectedina. | |
| JP2019534865A5 (https=) | ||
| JP2013544892A5 (https=) | ||
| JP2019065009A5 (https=) | ||
| MX2025009374A (es) | Compuesto que contiene trifluorometilsulfonilo |